AKOYA BIOSCIENCES INC (AKYA)

US00974H1041 - Common Stock

4.69  -0.04 (-0.85%)

After market: 4.69 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AKYA. AKYA was compared to 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of AKYA have multiple concerns. AKYA is valued quite expensively, but it does show have an excellent growth rating.



1

1. Profitability

1.1 Basic Checks

In the past year AKYA has reported negative net income.
In the past year AKYA has reported a negative cash flow from operations.
In the past 5 years AKYA always reported negative net income.
In the past 5 years AKYA always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -35.11%, AKYA is doing worse than 81.03% of the companies in the same industry.
AKYA's Return On Equity of -117.76% is on the low side compared to the rest of the industry. AKYA is outperformed by 86.21% of its industry peers.
Industry RankSector Rank
ROA -35.11%
ROE -117.76%
ROIC N/A
ROA(3y)-32.83%
ROA(5y)-29.39%
ROE(3y)-91.62%
ROE(5y)-89.72%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

AKYA has a better Gross Margin (58.27%) than 74.14% of its industry peers.
AKYA's Gross Margin has declined in the last couple of years.
AKYA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.54%
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKYA has more shares outstanding
AKYA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.64, we must say that AKYA is in the distress zone and has some risk of bankruptcy.
AKYA has a worse Altman-Z score (-0.64) than 75.86% of its industry peers.
A Debt/Equity ratio of 1.41 is on the high side and indicates that AKYA has dependencies on debt financing.
With a Debt to Equity ratio value of 1.41, AKYA is not doing good in the industry: 84.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF N/A
Altman-Z -0.64
ROIC/WACCN/A
WACC12.59%

2.3 Liquidity

AKYA has a Current Ratio of 3.45. This indicates that AKYA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.45, AKYA is in the better half of the industry, outperforming 62.07% of the companies in the same industry.
AKYA has a Quick Ratio of 2.94. This indicates that AKYA is financially healthy and has no problem in meeting its short term obligations.
AKYA has a better Quick ratio (2.94) than 62.07% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 2.94

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.94% over the past year.
AKYA shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.11%.
AKYA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.56% yearly.
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q56%
Revenue 1Y (TTM)29.11%
Revenue growth 3Y31.56%
Revenue growth 5YN/A
Revenue growth Q2Q24.82%

3.2 Future

AKYA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.60% yearly.
AKYA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.04% yearly.
EPS Next Y35.98%
EPS Next 2Y25.42%
EPS Next 3Y21.49%
EPS Next 5Y17.6%
Revenue Next Year21.96%
Revenue Next 2Y22.14%
Revenue Next 3Y23.55%
Revenue Next 5Y21.04%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AKYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

AKYA's earnings are expected to grow with 21.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.42%
EPS Next 3Y21.49%

0

5. Dividend

5.1 Amount

No dividends for AKYA!.
Industry RankSector Rank
Dividend Yield N/A

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (3/28/2024, 8:00:00 PM)

After market: 4.69 0 (0%)

4.69

-0.04 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap230.47M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.11%
ROE -117.76%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 58.27%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.45
Quick Ratio 2.94
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y35.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)29.11%
Revenue growth 3Y31.56%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y